Prostate cancer screening depends on a careful balance of benefits, in terms of reduced prostate cancer mortality, and harms, in terms of overdiagnosis and overtreatment. We aimed to estimate the effect on overdiagnosis of restricting prostate specific antigen (PSA) testing by age and baseline PSA.
Estimates of the effects of age on overdiagnosis were based on population based incidence data from the US Surveillance, Epidemiology and End Results database. To investigate the relationship between PSA and overdiagnosis, we used two separate cohorts subject to PSA testing in clinical trials (n = 1,577 and n = 1,197) and a population-based cohort of Swedish men not subject to PSA-screening followed for 25 years (n = 1,162).
If PSA testing had been restricted to younger men, the number of excess cases associated with the introduction of PSA in the US would have been reduced by 85%, 68% and 42% for age cut-offs of 60, 65 and 70, respectively. The risk that a man with screen-detected cancer at age 60 would not subsequently lead to prostate cancer morbidity or mortality decreased exponentially as PSA approached conventional biopsy thresholds. For PSAs below 1 ng/ml, the risk of a positive biopsy is 65 (95% CI 18.2, 72.9) times greater than subsequent prostate cancer mortality.
Prostate cancer overdiagnosis has a strong relationship to age and PSA level. Restricting screening in men over 60 to those with PSA above median (>1 ng/ml) and screening men over 70 only in selected circumstances would importantly reduce overdiagnosis and change the ratio of benefits to harms of PSA-screening.
Notes
Cites: N Engl J Med. 2012 Mar 15;366(11):981-9022417251
Cites: N Engl J Med. 2011 May 5;364(18):1708-1721542742
Cites: Eur Urol. 2012 Aug;62(2):204-922541389
Cites: Ann Intern Med. 2012 Jul 17;157(2):120-3422801674
Cites: N Engl J Med. 2012 Jul 19;367(3):203-1322808955
Cites: N Engl J Med. 2012 Aug 16;367(7):595-60522894572
Cites: J Natl Cancer Inst. 2012 Sep 5;104(17):1335-4222835388
Cites: Cancer. 2012 Dec 1;118(23):5955-6322605665
Cites: CA Cancer J Clin. 2013 Jan;63(1):11-3023335087
Cites: Int J Cancer. 2004 Jan 1;108(1):122-914618626
Cites: Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):373-715006911
Cites: Lancet. 1994 Dec 10;344(8937):1594-87527116
Cites: J Natl Cancer Inst. 1995 Mar 1;87(5):354-607531773
Cites: Clin Chem. 2006 Feb;52(2):235-916384894
Cites: J Natl Cancer Inst. 2006 Apr 19;98(8):529-3416622122
Cites: J Natl Cancer Inst. 2006 Nov 1;98(21):1521-717077354
Cites: J Clin Oncol. 2007 Feb 1;25(4):431-617264339
Cites: J Natl Cancer Inst. 2007 Aug 1;99(15):1171-717652279
Cites: Biometrics. 2008 Mar;64(1):10-917501937
Cites: N Engl J Med. 2008 Nov 20;359(21):2220-3219020324
Cites: J Natl Cancer Inst. 2009 Mar 18;101(6):374-8319276453
Cites: J Natl Cancer Inst. 2009 Oct 7;101(19):1325-919720969
Cites: Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1201-720406957